Dr. Oh on Remaining Challenges With Docetaxel in Prostate Cancer
January 20th 2017William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, Mount Sinai School of Medicine, discusses the challenges that remain with the use of docetaxel to treat patients with prostate cancer.
Dr. Oh on the Safety Profile of Docetaxel in Prostate Cancer
January 6th 2017William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, Mount Sinai School of Medicine, discusses the safety profile of docetaxel when administered to patients with prostate cancer.
Dr. Jagannath on Sequencing Therapies for Patients With Multiple Myeloma
March 2nd 2016Sundar Jagannath, MD, director of the Multiple Myeloma Program, professor of Medicine (Hematology and Medical Oncology), Tisch Cancer Institute at Mount Sinai School of Medicine, discusses sequencing challenges with therapies for patients with multiple myeloma.
Renowned Myeloma Expert Joins Mount Sinai
Bart Barlogie, MD, world-renowned myeloma expert who introduced the first curative therapy, a multi-drug regimen known as Total therapy 3, for multiple myeloma joins the faculty of Tisch Cancer Institute of the Icahn School of Medicine at Mount Sinai.
Immunotherapy Advances in Melanoma
July 28th 2014Melanoma care has fortunately undergone a whirlwind of changes over the past several years. Novel immunotherapies are perhaps the most exciting recent development in cancer care because patients can enjoy long-term benefit from these treatments, meaning that they are possibly "cured."
Dr. Galsky on the Role of Ipilimumab in Bladder Cancer
December 5th 2013Matthew D. Galsky, MD, assistant professor of medicine, Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, director, Genitourinary Medical Oncology, Tisch Cancer Institute at Mount Sinai Medical Center, discusses the role of ipilimumab in bladder cancer.